SCHEMBL21958073

SCHEMBL21958073

CCO/C=C/c1cccnc1C(=O)OC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.48
▸ BRD4 O60885 1/20 0.43
▸ HTT P42858 2/20 0.40
▸ ALOX15 P16050 2/20 0.40
▸ ALDH1A1 P00352 6/20 0.38
▸ KDM4E B2RXH2 4/20 0.38
▸ MAPT P10636 2/20 0.38
▸ GRM5 P41594 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ NFE2L2 Q16236 1/20 0.37
▸ MAP2K1 Q02750 1/20 0.37
▸ PARP1 P09874 1/20 0.37
▸ GAA P10253 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ MAPK1 P28482 2/20 0.36
▸ PKM P14618 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31245515 1.00 L3MBTL1 (0.48) L3MBTL1BRD4HTTALOX15ALDH1A1
SCHEMBL29987434 0.84 BRD4 (0.41) L3MBTL1BRD4HTTALOX15ALDH1A1
SCHEMBL31165179 0.81 NPSR1 (0.33) L3MBTL1HTTALOX15KDM4ESMN1; SMN2
SCHEMBL9000394 0.78 L3MBTL1 (0.51) L3MBTL1BRD4HTTALOX15ALDH1A1
SCHEMBL2561503 0.77 L3MBTL1 (0.57) L3MBTL1BRD4HTTALOX15ALDH1A1
SCHEMBL20477221 0.77 L3MBTL1 (0.37) L3MBTL1ALDH1A1KDM4EMAPTSMN1; SMN2
SCHEMBL21957872 0.77 BACE1 (0.53) ALOX15ALDH1A1KDM4EMAPTSMN1; SMN2
SCHEMBL535731 0.76 L3MBTL1 (0.55) L3MBTL1BRD4HTTALOX15ALDH1A1
SCHEMBL852328 0.76 L3MBTL1 (0.49) L3MBTL1BRD4HTTALOX15ALDH1A1
SCHEMBL852327 0.76 L3MBTL1 (0.49) L3MBTL1BRD4HTTALOX15ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260103454-A1 MODULATORS OF HEMOGLOBIN GLOBAL BLOOD THERAPEUTICS INC (US) 2026-04-16 — — US disclosed
US-20230159507-A1 MODULATORS OF HEMOGLOBIN GLOBAL BLOOD THERAPEUTICS, INC. 2023-05-25 — — US disclosed
US-20230159507-A1 MODULATORS OF HEMOGLOBIN GLOBAL BLOOD THERAPEUTICS, INC. 2023-05-25 — — US disclosed
US-20230159507-A1 MODULATORS OF HEMOGLOBIN GLOBAL BLOOD THERAPEUTICS, INC. 2023-05-25 — — US disclosed
US-11548880-B2 Modulators of hemoglobin GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-01-10 — — US disclosed
US-11548880-B2 Modulators of hemoglobin GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-01-10 — — US disclosed
EP-4046988-A1 2-FORMYL-3-HYDROXYPHENYLOXYMETHYL COMPOUNDS CAPABLE OF MODULATING HEMOGLOBIN Global Blood Therapeutics, Inc. (US) 2022-08-24 — — EP disclosed
EP-3880654-B1 2-FORMYL-3-HYDROXYPHENYLOXYMETHYL COMPOUNDS CAPABLE OF MODULATING HEMOGLOBIN GLOBAL BLOOD THERAPEUTICS INC (US) 2021-12-29 — — EP disclosed
EP-3880654-A1 2-FORMYL-3-HYDROXYPHENYLOXYMETHYL COMPOUNDS CAPABLE OF MODULATING HEMOGLOBIN Global Blood Therapeutics, Inc. (US) 2021-09-22 — — EP disclosed
CN-113316568-A 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin 全球血液疗法股份有限公司 2021-08-27 — — CN disclosed
US-20210047309-A1 MODULATORS OF HEMOGLOBIN GLOBAL BLOOD THERAPEUTICS, INC. 2021-02-18 — — US disclosed
US-20210047309-A1 MODULATORS OF HEMOGLOBIN GLOBAL BLOOD THERAPEUTICS, INC. 2021-02-18 — — US disclosed
US-10683285-B2 Modulators of hemoglobin GLOBAL BLOOD THERAPEUTICS, INC. (US) 2020-06-16 — — US disclosed
US-10683285-B2 Modulators of hemoglobin GLOBAL BLOOD THERAPEUTICS, INC. (US) 2020-06-16 — — US disclosed
US-20200157085-A1 MODULATORS OF HEMOGLOBIN GLOBAL BLOOD THERAPEUTICS, INC. 2020-05-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200157085-A1 MODULATORS OF HEMOGLOBIN HBG1, HBG2, HBB L3MBTL1 3699/4885BRD4 4537/4885HTT 661/4885
US-10683285-B2 Modulators of hemoglobin HBG1, HBG2, HBB L3MBTL1 3699/4885BRD4 4537/4885HTT 661/4885
US-20210047309-A1 MODULATORS OF HEMOGLOBIN HBG1, HBG2, HBB L3MBTL1 3699/4885BRD4 4537/4885HTT 661/4885
US-20230159507-A1 MODULATORS OF HEMOGLOBIN HBG1, HBG2, HBB L3MBTL1 3699/4885BRD4 4537/4885HTT 661/4885
US-20260103454-A1 MODULATORS OF HEMOGLOBIN HBZ, HBB, HBG2 L3MBTL1 4612/4885BRD4 4801/4885HTT 1211/4885
US-11548880-B2 Modulators of hemoglobin HBG1, HBG2, HBB L3MBTL1 3699/4885BRD4 4537/4885HTT 661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback